KRTL Holding Group Inc. (OTC: KRTL) has completed a strategic merger between its subsidiary, KRTL Biotech Inc., and Bolivian pharmaceutical company Industria Químico Farmacéutica Sigma Corp. S.R.L. (SIGMA). The agreement, finalized on Sept. 2, 2025, gives KRTL Biotech a 99% controlling interest in SIGMA, in exchange for 49% ownership in KRTL Biotech by SIGMA’s founding Wilstermann family.
Under the terms of the deal, KRTL Biotech issued 490 million common shares to the Wilstermann family. Additionally, Patricia Wilstermann, SIGMA’s CEO, was granted a preferred share and a permanent seat on KRTL Holding’s board—ensuring continued influence and continuity from the Bolivian side.
While SIGMA will retain its local management and operations, its financials will now be consolidated into KRTL Biotech’s U.S. financial reporting, allowing for enhanced global alignment and regulatory transparency under U.S. GAAP standards.
KRTL Holding Group CEO César Herrera called the deal a “major step” in the company’s international growth strategy, emphasizing the synergy between SIGMA’s manufacturing expertise and KRTL Biotech’s regulatory and compliance infrastructure in the U.S.
Dan Bishop, CEO of KRTL Biotech, said the merger will enable both companies to scale pharmaceutical manufacturing, distribution, and innovation across both the U.S. and Latin America. “Together, we’re positioned to better serve international markets while maintaining the highest quality standards,” he said.
The partnership is expected to facilitate two-way pharmaceutical trade—allowing products developed in the U.S. to be manufactured and distributed in Latin America and vice versa. SIGMA’s operational capabilities in Bolivia will support scalable, cross-border production, while KRTL’s U.S. framework ensures regulatory rigor and market access.
“We’re excited to maintain our Bolivian roots while expanding into global markets,” said Patricia Wilstermann. “This collaboration honors SIGMA’s legacy while positioning us for long-term scientific and commercial success.”
The merger strengthens KRTL’s presence in Latin America and sets a foundation for broader biotech and pharmaceutical expansion in emerging markets.
